BioSpace News Archive

Enteric illnesses are intestinal infections triggered by a number of bacteria, viruses, and parasites such as salmonella, shigella, Giardia lamblia, campylobacter, cryptosporidium, and vibrio cholerae.

TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors.

The increasing need for improving patient care and reducing treatment costs is a primary factor augmenting the growth of global artificial intelligence in the diagnostics market.

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach.

BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, and Merck, a leading science and technology company, announce an agreement for the development and supply of a specific version of Mallya device to monitor treatment adherence in the field of HGH.

Leap Therapeutics, Inc. announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap’s anti-Dickkopf-1 antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer, at the European Society for Medical Oncology Congress.

Oxitope Pharma B.V., a company committed to enabling people to live longer and healthier lives by treating diseases driven by oxidative stress, announces its official launch after having been operational since March 2020.

Allarity Therapeutics A/S announced validation results for its Dovitinib DRP® companion diagnostic utilizing data from Novartis’ prior Phase III trial of dovitinib in renal cell carcinoma, which will be included in a poster presentation at the European Society for Medical Oncology 2021 Virtual Congress taking place from September 16 until September 21, 2021.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that new clinical data for zanidatamab, a HER2‑targeted bispecific antibody, demonstrate promising response rates and durability in first-line HER2-positive GEA.

Xilio Therapeutics, Inc. a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, announced that the first patient has been dosed in the company’s Phase 1/2 clinical trial evaluating XTX101 for the treatment of solid tumors.